Cochlear's share price slumps as it recalls implant on failure risk
This article was originally published in Clinica
Executive Summary
Australian hearing implant specialist Cochlear is recalling its Nucleus CI500 range of cochlear implants after seeing an increased failure rate with one of the product models, the Nucleus CI512. In the event of failure, the device safely shuts down without injuring the recipient, according to Cochlear, the number-one firm in the cochlear implant market.